Supernus Pharmaceuticals, Inc. (SUPN) has reported an 113.41 percent jump in profit for the quarter ended Mar. 31, 2017. The company has earned $10.30 million, or $0.19 a share in the quarter, compared with $4.82 million, or $0.08 a share for the same period last year.

Revenue during the quarter surged 30.28 percent to $57.58 million from $44.19 million in the previous year period. Gross margin for the quarter contracted 52 basis points over the previous year period to 94.88 percent. Total expenses were 70.84 percent of quarterly revenues, down from 85.43 percent for the same period last year. This has led to an improvement of 1459 basis points in operating margin to 29.16 percent.

Operating income for the quarter was $16.79 million, compared with $6.44 million in the previous year period.

"We are excited about the launch of Trokendi XR in migraine, and are very encouraged by the early IMS prescription data. We continue to believe that the migraine indication should allow us to realize the full potential of Trokendi XR," said Jack Khattar, president and chief executive officer of Supernus Pharmaceuticals. "Trokendi XR, with its novel formulation, provides full 24 hour coverage for patients with smooth pharmacokinetics compared to immediate-release topiramate products, making it an important new prophylactic treatment option for adult and adolescent patients suffering from migraine headache."

For financial year 2017, Supernus Pharmaceuticals, Inc. forecasts revenue to be in the range of $265 million to $275 million. The company forecasts operating income to be in the range of $75 million to $80 million.